JP2015514110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514110A5 JP2015514110A5 JP2015504677A JP2015504677A JP2015514110A5 JP 2015514110 A5 JP2015514110 A5 JP 2015514110A5 JP 2015504677 A JP2015504677 A JP 2015504677A JP 2015504677 A JP2015504677 A JP 2015504677A JP 2015514110 A5 JP2015514110 A5 JP 2015514110A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- hla
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618969P | 2012-04-02 | 2012-04-02 | |
| US61/618,969 | 2012-04-02 | ||
| US201361778703P | 2013-03-13 | 2013-03-13 | |
| US61/778,703 | 2013-03-13 | ||
| PCT/US2013/034952 WO2013152001A2 (en) | 2012-04-02 | 2013-04-02 | Anti-hla-b*27 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514110A JP2015514110A (ja) | 2015-05-18 |
| JP2015514110A5 true JP2015514110A5 (https=) | 2016-05-26 |
| JP6320993B2 JP6320993B2 (ja) | 2018-05-09 |
Family
ID=48093122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504677A Expired - Fee Related JP6320993B2 (ja) | 2012-04-02 | 2013-04-02 | 抗ｈｌａ−ｂ＊２７抗体およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9790273B2 (https=) |
| EP (1) | EP2834272B1 (https=) |
| JP (1) | JP6320993B2 (https=) |
| KR (1) | KR20150003256A (https=) |
| CN (1) | CN104169302A (https=) |
| AR (1) | AR090585A1 (https=) |
| AU (1) | AU2013243644C1 (https=) |
| BR (1) | BR112014024622A2 (https=) |
| CA (1) | CA2868907C (https=) |
| CL (1) | CL2014002631A1 (https=) |
| CO (1) | CO7121320A2 (https=) |
| EA (1) | EA201491827A1 (https=) |
| HK (1) | HK1207092A1 (https=) |
| IL (2) | IL234707A0 (https=) |
| MX (1) | MX365690B (https=) |
| MY (1) | MY171180A (https=) |
| NZ (1) | NZ700650A (https=) |
| PH (1) | PH12014502184A1 (https=) |
| SG (2) | SG11201405759UA (https=) |
| TW (1) | TWI619729B (https=) |
| UY (1) | UY34721A (https=) |
| WO (1) | WO2013152001A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| TWI687439B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| KR20230143201A (ko) | 2011-11-30 | 2023-10-11 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| CN110241137A (zh) | 2012-07-27 | 2019-09-17 | 希望之城 | 一种递送ul128复合体和预防cmv感染的mva疫苗 |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| ES2876009T3 (es) | 2012-12-27 | 2021-11-11 | Chugai Pharmaceutical Co Ltd | Polipéptido heterodimerizado |
| CN105246914B (zh) | 2013-04-02 | 2021-08-27 | 中外制药株式会社 | Fc区变体 |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| CA2973641A1 (en) * | 2015-02-04 | 2016-08-11 | Universitat Zurich | Use of hla-b27 homodimers for cancer treatment |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| JP7237449B2 (ja) * | 2015-02-27 | 2023-03-13 | アイセル・ジーン・セラピューティクス・エルエルシー | 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| US11655452B2 (en) | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| EP3341738A4 (en) | 2015-08-24 | 2019-02-27 | University of Cincinnati | METHOD AND COMPOSITIONS FOR DETECTING FC RECEPTOR BINDING ACTIVITY OF ANTIBODIES |
| WO2017044895A2 (en) * | 2015-09-10 | 2017-03-16 | City Of Hope | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF |
| AR107078A1 (es) * | 2015-12-18 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso |
| HUE065073T2 (hu) * | 2015-12-18 | 2024-04-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| AU2017230855B2 (en) | 2016-03-08 | 2021-05-27 | Universität Basel | HLA-B57 open conformers |
| CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| JP7010439B2 (ja) | 2016-08-10 | 2022-01-26 | ウニヴェルズィテート チューリッヒ | ＭＨＣクラスＩａオープンコンフォーマー |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| EP3600376A1 (en) * | 2017-03-31 | 2020-02-05 | Alma Bio Therapeutics | Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same |
| CA3287539A1 (en) | 2017-06-21 | 2026-03-02 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| EP4640703A3 (en) | 2017-11-14 | 2026-04-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| CN108486226B (zh) * | 2018-04-01 | 2022-04-12 | 广东辉锦创兴生物医学科技有限公司 | Hla-b27等位基因的检测试剂盒及其应用 |
| KR102259473B1 (ko) | 2018-08-10 | 2021-06-02 | 추가이 세이야쿠 가부시키가이샤 | 항cd137 항원 결합 분자 및 그의 사용 |
| IL286482B2 (en) * | 2019-03-21 | 2025-01-01 | Gamida Cell Ltd | Cultured NK cell fractions for use in combination therapy |
| EP4696320A2 (en) | 2019-05-15 | 2026-02-18 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibody |
| CN111175490A (zh) * | 2020-01-19 | 2020-05-19 | 泛肽生物科技(浙江)有限公司 | 一种定性检测hla-b27的试剂盒及其检测方法 |
| JP2024515240A (ja) * | 2021-04-07 | 2024-04-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍｈｃ－ｉ病の治療に使用するための組成物 |
| EP4416286A1 (en) * | 2021-10-14 | 2024-08-21 | Regeneron Pharmaceuticals, Inc. | Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors |
| US20250302956A1 (en) * | 2022-05-13 | 2025-10-02 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for modulating tcr specificity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0213824B1 (en) * | 1985-08-16 | 1995-05-24 | Genetic Systems Corporation | Monoclonal antibody to polymorphic HLA determinant-B27 |
| US5369010A (en) | 1985-08-16 | 1994-11-29 | Genetic Systems Corporation | Monoclonal antibody to polymorphic HLA determinant -B27 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5734023A (en) * | 1991-11-19 | 1998-03-31 | Anergen Inc. | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US20130315933A1 (en) | 2010-10-06 | 2013-11-28 | Christoph Renner | Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
-
2013
- 2013-04-01 TW TW102111629A patent/TWI619729B/zh not_active IP Right Cessation
- 2013-04-02 KR KR20147030831A patent/KR20150003256A/ko not_active Withdrawn
- 2013-04-02 SG SG11201405759UA patent/SG11201405759UA/en unknown
- 2013-04-02 NZ NZ700650A patent/NZ700650A/en not_active IP Right Cessation
- 2013-04-02 BR BR112014024622A patent/BR112014024622A2/pt not_active IP Right Cessation
- 2013-04-02 SG SG10201608136SA patent/SG10201608136SA/en unknown
- 2013-04-02 JP JP2015504677A patent/JP6320993B2/ja not_active Expired - Fee Related
- 2013-04-02 US US13/855,448 patent/US9790273B2/en not_active Expired - Fee Related
- 2013-04-02 UY UY0001034721A patent/UY34721A/es not_active Application Discontinuation
- 2013-04-02 CN CN201380015594.7A patent/CN104169302A/zh active Pending
- 2013-04-02 MY MYPI2014002668A patent/MY171180A/en unknown
- 2013-04-02 EA EA201491827A patent/EA201491827A1/ru unknown
- 2013-04-02 WO PCT/US2013/034952 patent/WO2013152001A2/en not_active Ceased
- 2013-04-02 MX MX2014011898A patent/MX365690B/es active IP Right Grant
- 2013-04-02 EP EP13716138.6A patent/EP2834272B1/en active Active
- 2013-04-02 CA CA2868907A patent/CA2868907C/en active Active
- 2013-04-02 AU AU2013243644A patent/AU2013243644C1/en not_active Ceased
- 2013-04-02 HK HK15107698.3A patent/HK1207092A1/xx unknown
- 2013-04-03 AR ARP130101081A patent/AR090585A1/es unknown
-
2014
- 2014-09-17 IL IL234707A patent/IL234707A0/en unknown
- 2014-09-29 PH PH12014502184A patent/PH12014502184A1/en unknown
- 2014-09-30 CL CL2014002631A patent/CL2014002631A1/es unknown
- 2014-10-30 CO CO14241139A patent/CO7121320A2/es unknown
-
2018
- 2018-01-03 IL IL256716A patent/IL256716A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514110A5 (https=) | ||
| JP2017505125A5 (https=) | ||
| JP2013542194A5 (https=) | ||
| JP2015503909A5 (https=) | ||
| JP2015535828A5 (https=) | ||
| SI3042917T1 (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| JP2018500014A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2018021031A5 (https=) | ||
| JP2016507470A5 (https=) | ||
| JP2025131696A5 (https=) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2018536393A5 (https=) | ||
| JP2012523417A5 (https=) | ||
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| JP2015525795A5 (https=) | ||
| JP2013542191A5 (https=) | ||
| JP2023055904A5 (https=) | ||
| JP2011509245A5 (https=) | ||
| ME02798B (me) | Protutijela protiv dkk-1" | |
| JP2016519650A5 (https=) | ||
| JP2018507220A5 (https=) | ||
| JP2014205674A5 (https=) | ||
| JP2020502198A5 (https=) | ||
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) |